UY25512A1 - Preparaciones farmaceuticas estabilizadas de gabapentina, y proceso para prepararla - Google Patents

Preparaciones farmaceuticas estabilizadas de gabapentina, y proceso para prepararla

Info

Publication number
UY25512A1
UY25512A1 UY25512A UY25512A UY25512A1 UY 25512 A1 UY25512 A1 UY 25512A1 UY 25512 A UY25512 A UY 25512A UY 25512 A UY25512 A UY 25512A UY 25512 A1 UY25512 A1 UY 25512A1
Authority
UY
Uruguay
Prior art keywords
gabapentin
preparation
preparing
pharmaceutical preparations
stabilized
Prior art date
Application number
UY25512A
Other languages
English (en)
Inventor
Akira Aomatsu
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25512(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY25512A1 publication Critical patent/UY25512A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymerisation Methods In General (AREA)

Abstract

La presente invención se refiere a una preparación farmacéutica estabilizada sólida o líquida del derivado del ácido 4-amino-3-sustituido-butanoico, incluyendo gabapentina, pregabalina o baclofeno, en las formas de dosificación de comprimidos, polvos, gránulos y cápsulas y una preparación farmacéutica estabilizada líquida en las formas de dosificación de preparaciones líquidas, jarabes e inyecciones, así como también un proceso para la preparación de las mismas. La gabapentina (ácido 1-(Aminometil) ciclohexanoacético) se usa como un medicamento para el tratamiento de ciertos trastornos del sistema nervioso, tales como epilepsia, enfermedad de Alzheimer o enfermedad de Parkinson.
UY25512A 1998-05-15 1999-05-14 Preparaciones farmaceuticas estabilizadas de gabapentina, y proceso para prepararla UY25512A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13311398 1998-05-15

Publications (1)

Publication Number Publication Date
UY25512A1 true UY25512A1 (es) 1999-07-19

Family

ID=15097118

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25512A UY25512A1 (es) 1998-05-15 1999-05-14 Preparaciones farmaceuticas estabilizadas de gabapentina, y proceso para prepararla

Country Status (37)

Country Link
US (1) US7309719B1 (es)
EP (1) EP1077692B1 (es)
JP (1) JP4612923B2 (es)
KR (1) KR100602047B1 (es)
CN (1) CN1303991C (es)
AR (1) AR020323A1 (es)
AT (1) ATE271864T1 (es)
AU (1) AU768277B2 (es)
BR (1) BR9910508B1 (es)
CA (1) CA2327285C (es)
CO (1) CO5021224A1 (es)
CR (1) CR6026A (es)
CU (1) CU23253B7 (es)
DE (1) DE69918977T2 (es)
DK (1) DK1077692T3 (es)
EG (1) EG26803A (es)
ES (1) ES2221385T3 (es)
GT (1) GT199900069A (es)
HK (1) HK1036586A1 (es)
HN (1) HN1999000072A (es)
HU (1) HU228771B1 (es)
ID (1) ID27724A (es)
IL (2) IL139298A0 (es)
IS (1) IS2233B (es)
MY (1) MY157878A (es)
NO (1) NO328959B1 (es)
NZ (1) NZ508015A (es)
PA (1) PA8472801A1 (es)
PE (1) PE20000556A1 (es)
PL (1) PL204921B1 (es)
PT (1) PT1077692E (es)
SI (1) SI1077692T1 (es)
SV (1) SV1999000064A (es)
TW (1) TWI243054B (es)
UY (1) UY25512A1 (es)
WO (1) WO1999059573A1 (es)
ZA (1) ZA200006484B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9710536A (pt) 1996-07-24 1999-08-17 Warner Lambert Co Isobutilgaba e seus derivados para o tratamento da dor
PT1289364E (pt) * 2000-06-16 2004-04-30 Teva Pharma Gabapentina estavel contendo mais do que 20 ppm de iao cloreto
HUP0301919A3 (en) * 2000-06-16 2006-01-30 Teva Pharma Stable gabapentin having ph within a controlled range
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
EP1430893A1 (en) * 2000-06-16 2004-06-23 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chloride ion
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
NZ529173A (en) * 2001-05-25 2005-07-29 Warner Lambert Co Stable liquid pharmaceutical composition comprising a GABA analog i.e. gabapentin or pregabalin, and a polyhydric alcohol e.g. glycerol, xylitol, sorbitol, mannitol
KR20070000439A (ko) * 2004-02-04 2007-01-02 알렘빅 리미티드 벤라팍신 히드로클로라이드의 방출연장형 코팅 미니정제
EP1761255A1 (en) * 2004-05-17 2007-03-14 Odessa Pharma LLC Decreasing brain neuronal glutamate levels using alpha-keto branched chain amino acids
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007107835A2 (en) * 2006-03-17 2007-09-27 Aurobindo Pharma Limited Stable liquid formulations of antiepileptic agents
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
DK2432454T3 (en) * 2009-05-19 2017-06-19 Neuroderm Ltd COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA DECARBOXYLASE INHIBITORS
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
EP2389934A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
EP2389933A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Pregabalin Compositions
TR201005241A1 (tr) 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
PL3326615T3 (pl) 2010-11-15 2020-07-27 Neuroderm Ltd Ciągłe podawanie L-dopy, inhibitorów dekarboksylazy dopy, inhibitorów katecholo-o-metylotransferazy i ich kompozycji
HUE042425T2 (hu) 2012-06-05 2019-06-28 Neuroderm Ltd Apomorfint és szerves savakat tartalmazó készítmények és alkalmazásaik
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
EP3099288A1 (en) 2014-01-28 2016-12-07 Sun Pharmaceutical Industries Ltd Stabilized gastroretentive tablets of pregabalin
EP4299128A3 (en) 2014-03-13 2024-04-17 Neuroderm Ltd. Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP2923694B1 (en) * 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
EP2929878A1 (en) * 2014-04-09 2015-10-14 Arven Ilac Sanayi ve Ticaret A.S. Extended release formulations of gabapentin
WO2016187718A1 (en) 2015-05-26 2016-12-01 Isa Odidi Controlled extended release pregabalin
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
JPWO2020071546A1 (ja) 2018-10-04 2021-09-02 株式会社 メドレックス 非水系溶媒により安定化された製剤
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
JPWO2021079887A1 (es) 2019-10-25 2021-04-29
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
CN112843015A (zh) * 2021-04-08 2021-05-28 海南鑫开源医药科技有限公司 一种加巴喷丁胶囊制剂及其制备方法
WO2023055457A1 (en) 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4255448A (en) * 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
GB8311804D0 (en) * 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
US4595697A (en) * 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
CA1249968A (en) * 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
JPS63253022A (ja) 1987-04-08 1988-10-20 Nitto Electric Ind Co Ltd バクロフエン外用製剤
PH26730A (en) 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5006560A (en) * 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
EP0458751A1 (en) * 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
HUT59656A (en) * 1990-11-15 1992-06-29 Puetter Medice Chem Pharm Process for producing s/+/-phenyl-alkanoic acids and alpha-amino-acids containing complexes and pharmaceutical compositions containing them as active components
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
JPH0597703A (ja) * 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
RU94046105A (ru) * 1992-05-20 1997-06-20 Нортвестерн Юниверсити (Us) АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5248678A (en) * 1992-06-30 1993-09-28 Fractal Laboratories, Inc. Methods for increasing arousal and alertness and for the amelioration of comatose states
US5260337A (en) * 1992-07-29 1993-11-09 Merck & Co., Inc. Ibuprofen-muscle relaxant combinations
JP3467794B2 (ja) * 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
JPH0867636A (ja) * 1994-08-30 1996-03-12 Yamanouchi Pharmaceut Co Ltd 播種性血管内凝固症候群（ｄｉｃ）の予防治療薬
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
JPH1017476A (ja) * 1996-06-28 1998-01-20 Nippon Seiyaku Kk 敗血症用非経口製剤及びそれによる予防及び治療方法
WO1998003189A1 (en) * 1996-07-22 1998-01-29 Cognetix, Inc. Use of conantokins
BR9710536A (pt) * 1996-07-24 1999-08-17 Warner Lambert Co Isobutilgaba e seus derivados para o tratamento da dor
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
IT1311984B1 (it) * 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
ES2296956T5 (es) * 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.

Also Published As

Publication number Publication date
PT1077692E (pt) 2004-12-31
BR9910508A (pt) 2001-01-02
PE20000556A1 (es) 2000-08-10
CR6026A (es) 2008-08-26
US7309719B1 (en) 2007-12-18
MY157878A (en) 2016-07-29
CO5021224A1 (es) 2001-03-27
BR9910508B1 (pt) 2012-01-24
PL344218A1 (en) 2001-10-08
CA2327285A1 (en) 1999-11-25
TWI243054B (en) 2005-11-11
JP2000034226A (ja) 2000-02-02
CN1303991C (zh) 2007-03-14
HU228771B1 (en) 2013-05-28
IS5666A (is) 2000-10-16
KR100602047B1 (ko) 2006-07-19
IS2233B (is) 2007-04-15
AU768277B2 (en) 2003-12-04
NO20005768D0 (no) 2000-11-14
ATE271864T1 (de) 2004-08-15
AU4073599A (en) 1999-12-06
EP1077692B1 (en) 2004-07-28
EG26803A (en) 2014-09-21
AR020323A1 (es) 2002-05-08
GT199900069A (es) 2000-11-04
IL139298A (en) 2009-07-20
HN1999000072A (es) 2000-06-05
DK1077692T3 (da) 2004-12-06
CN1301155A (zh) 2001-06-27
CU23253B7 (es) 2007-12-17
ZA200006484B (en) 2002-02-11
NO328959B1 (no) 2010-06-28
EP1077692A1 (en) 2001-02-28
NO20005768L (no) 2000-11-14
IL139298A0 (en) 2001-11-25
SV1999000064A (es) 2000-03-31
ID27724A (id) 2001-04-26
DE69918977D1 (de) 2004-09-02
JP4612923B2 (ja) 2011-01-12
HK1036586A1 (en) 2002-01-11
SI1077692T1 (en) 2004-10-31
CA2327285C (en) 2005-06-14
KR20010043611A (ko) 2001-05-25
NZ508015A (en) 2003-11-28
PA8472801A1 (es) 2001-12-14
ES2221385T3 (es) 2004-12-16
PL204921B1 (pl) 2010-02-26
WO1999059573A9 (en) 2000-05-04
WO1999059573A1 (en) 1999-11-25
HUP0102022A2 (hu) 2001-11-28
DE69918977T2 (de) 2005-07-28
HUP0102022A3 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
UY25512A1 (es) Preparaciones farmaceuticas estabilizadas de gabapentina, y proceso para prepararla
UY25513A1 (es) Composiciones sólidas que contienen gabapentina y proceso para su preparación
ES2200184T7 (es) Isobutilgaba y sus derivados para el tratamiento del dolor
Blaylock et al. Immunoexcitotoxicity as a Central Mechanism of Chronic Traumatic Encephalopathy–A Unifying Hypothesis
Lauria-Horner et al. Pregabalin: a new anxiolytic
US20220133685A1 (en) Fast-acting plant-based medicinal compounds and nutritional supplements
KR20180134402A (ko) 속효성 식물-계 의약 화합물 및 영양 보충제
MEP44808A (en) Mono- and disubstituted 3-propyl gamma-aminobutyric acids
GEP20043297B (en) Bicyclic Amino Acids as Pharmaceutical Agents
KR20010071778A (ko) 불면증의 치료를 위한 ｇａｂａ 유사체의 용도
KR20200066319A (ko) 개선된 생체이용률을 갖는 약초 조성물
CN1806800A (zh) 一种以普瑞巴林为活性成分的药用组合物及其制备方法、用途
ZA912652B (en) Use of n-alkylated 1,4-dihydropyridinedicarboxylic acid esters as medicaments,new compounds and processes for their preparation
EP1171114B1 (en) Method for the treatment of incontinence
Sadeghnia et al. Berberine attenuates convulsing behavior and extracellular glutamate and aspartate changes in 4-aminopyridine treated rats
JP2023546140A (ja) パーキンソン病の治療のためのオピカポン及びレボドパ
Tiwari et al. A review on mechanistic and pharmacological findings of diabetic peripheral neuropathy including pharmacotherapy
Lim A walk through the management of Parkinson s disease
Mehan et al. Restoration of mitochondrial dysfunction in 6-hydroxydopamine induced Parkinson’s disease: a complete review
Kumar et al. Effects of stereoisomers on drug activity
CN102258507B (zh) 含有布洛芬的药物组合物
WO2019041423A1 (zh) A型肉毒毒素在抗抑郁症中的应用
Gjerris Transitory procaine-induced parkinsonism
CA2197176C (en) Use of selegiline for the treatment of epileptic disorders
KR20010071776A (ko) 대상포진의 치료를 위한 ｇａｂａ 유사체 및항바이러스제를 포함하는 제약 조성물

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20100317

VENC Patent expired

Effective date: 20190514